Pulmonary veno-occlusive disease
|
|
- Theodore Jenkins
- 6 years ago
- Views:
Transcription
1 Disclosure Objectives Pulmonary veno-occlusive disease Tilman Humpl The Hospital for Sick Children University of Toronto, Canada Advisor/Research Grants Actelion Pfizer Historical aspects Epidemiology/Genetics Clinical characteristics Pulmonary veno-occlusive disease 48 year old male Previously healthy One year history of weak heart Suspicion of mitral valve disease Autopsy Dilated right atrium and ventricle Sclerosis with intimal changes in pulmonary arteries Odd changes of the small pulmonary veins Isolated pulmonary venous sclerosis Obstructive disease of the pulmonary veins Clinico-pathologic syndrome Term coined st pediatric report: K. Weisser (1967) Frankfurter Z Pathol 47, Brown CH et al, Lancet 1966 Heath D et al, Circulation
2 Pathogenesis Unknown Multi-factorial Incidence - Adults Not precisely known Proportion of primary pulmonary hypertension fulfilling PVOD criteria 5-25% Incidence - Children 7 series of primary pulmonary hypertension patients PVOD present in 10% Mandel J et al., Am J Respir Crit Care 2000 Epidemiology - Risk factors First week of life 7 th decade Male : female 1 : 1 Chemotherapy Bleomycin, mitomycin, carmustine Post bone marrow transplantation Thoracic radiation Infection HIV Toxoplasma gondii Measles Collagen vascular disease Genetics - Familial pattern 8 weeks / 3 months 2 years 14 years / 13 years Several months Non-heritable risk factors not excluded Genetics - BMPR2 mutations Mutations present in ipah patients Similar pattern in PVOD Absence of mutations suggest other genetic risk factors Voordes CG et al, Thorax 1977 Davies P & Reid L, Hum Pathol 1982 Runo JR et al, Am J Respir Crit Care Med 2003 Machado RD et al, Hum Mut 2006 Aldred MA et al, Hum Mut
3 Clinical characteristics Similar to idiopathic PAH Worsening dyspnea Exertion, lethargy Chronic cough Hemoptysis Chest pain Right heart failure Pleural effusions FC III and IV Syncope Sudden death Disease process Natural history Progressive obstruction of small pulmonary veins Elevated pulmonary vascular resistance/pressure Right ventricular failure Death PVOD - PAH Time PVOD PAH p to death or LTx to death to LTx 1 st symptom to death or LTx 1 st symptom to death 1 st symptom to LTx ± ± ± ± ± ± ± ± ± ± ± ± < <0.001 < Pathology Postcapillary Septal veins Fibrous remodeling of intima Possible occlusion of lumen Interstitial edema Interlobular septal veins Centrilobular pulmonary artery Small pulmonary arteries Intimal fibrosis and medial hypertrophy Hemosiderosis Capillary network Frazier AA et al, RadioGraphics
4 Gold standard: histology Surgical risk Establishing diagnosis Listing for lung transplantation Pulmonary function testing Mild obstructive/restrictive pattern Normal mean values for FEV1 Normal ratio FEV1:FVC Normal TLC Lower DCLO Lower nadir pulse oxygen saturation 6MWT Computed tomography Holcomb BW Jr et al., Chest 2000 Resten A et al., AJR 2004 Computed tomography Ground-glass opacities Septal lines Pericardial/pleural effusion Lymph nodes Resten A et al., AJR
5 Hemodynamics Hemodynamics Wedge pressure does not reflect true capillary pressure Pressure in larger veins Normal wedge pressure No discrimination between ipah and PVOD Acute vasoreactivity testing Safe? Useful? ino 5-10 min 10ppm No pulmonary edema No prediction for Development of pulmonary edema Prognosis Montani et al., Eur Respir J 2009 Golde Score Bronchoalveolar lavage Alveolar haemorrhage Grading for hemosiderin p=0.02 Lack of controlled trials Anecdotal case reports/series Expert opinion Pulmonary vasodilators May cause increase of pulmonary arteriolar blood flow against fixed resistance Progress to severe pulmonary edema Rabiller A et al, Eur Respir J
6 Prostacyclin 12 adults, 41±12y to initiation: 66 (1-358) d Before PGI After 3-4 m p Class III 4 11 <0.01 Class IV 8 1 6MWT (m) 281± ± PVRi WUxm ±8.4 17±5.2 < Montani D et al., Eur Resp J 2009 Prostacyclin Maximal dose: 13 (5-22) ng kg -1 min -1 Time to reach maximal dose: 150 (5-1065) d Additional therapies Oxygen Anticoagulation Diuretics Endothelin receptor antagonist Dobutamine Montani D et al., Eur Resp J 2009 Prostacylin Lung transplantation: 9 (+1) patients Death: 2 patients Montani D et al., Eur Resp J 2009 Case reports/series Inhaled prostacyclin Oral phosphodiesterase inhibitors V Endothelin Receptor Antagonist Hoeper MM et al., Respir Med 1999 Barreto AC et al., Braz J Med Biol Res 2005 Kuroda T et al., Heart Lung Circ 2006 General measures Limit physical activity to tolerance O 2 to maintain saturations >90% Vaccinations Diuretics (Avoid tobacco exposure) Anticoagulation Based on data on primary pulmonary hypertension Immunosuppression Steroids Antimetabolites Experimental therapy Imatinib Antiproliferative effect Lung transplantation Overbeek MJ et al., Eur Resp J
7 Treatment failure for ipah Summary Take home Idiopathic/scleroderma-associated PAH Non-responders to medical therapy In retrospect: 86% PVOD Treatment refractory ipah In retrospect: 17.2% PVOD Rare subgroup of pulmonary hypertension Etiology in the majority of cases unknown Most likely underdiagnosed Combination of: CT, BAL, DLCO, SpO 2 Worse prognosis compared to ipah No specific medical treatment options Lung transplantation Eur Respir Rev 2009 Brown CH & Harrison CV, Lancet 1966 Harch S et al., Chest 2009 Dorfmüller P et al., Hum Pathol
Pulmonary veno-occlusive disease
Pulmonary veno-occlusive disease Dr David MONTANI French Referral Centre for Severe Pulmonary Hypertension Hôpital de Bicêtre, DHU Thorax Innovation INSERM U999, LabEx LERMIT Université Paris-Sud CLASSIFICATION
More informationPulmonary Hypertension in 2012
Pulmonary Hypertension in 2012 Evan Brittain, MD December 7, 2012 Kingston, Jamaica VanderbiltHeart.com Disclosures None VanderbiltHeart.com Outline Definition and Classification of PH Hemodynamics of
More informationChapter. Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension
Chapter 7 Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension P. Trip B. Girerd H.J. Bogaard F.S. de Man A. Boonstra G. Garcia M. Humbert D. Montani A. Vonk Noordegraaf Eur Respir
More informationPulmonary arterial hypertension. Pulmonary arterial hypertension: newer therapies. Definition of PH 12/18/16. WHO Group classification of PH
Pulmonary arterial hypertension Pulmonary arterial hypertension: newer therapies Ramona L. Doyle, MD Clinical Professor of Medicine, UCSF Attending Physician UCSF PH Clinic Definition and classification
More informationPulmonary Hypertension: Another Use for Viagra
Pulmonary Hypertension: Another Use for Viagra Kathleen Tong, MD Director, Heart Failure Program Assistant Clinical Professor University of California, Davis Disclosures I have no financial conflicts A
More informationPULMONARY HYPERTENSION
PULMONARY HYPERTENSION REVIEW & UPDATE Olga M. Fortenko, M.D. Pulmonary & Critical Care Medicine Pulmonary Vascular Diseases Sequoia Hospital 650-216-9000 Olga.Fortenko@dignityhealth.org Disclosures None
More informationSeverely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses
ORIGINAL ARTICLE PULMONARY VASCULAR DISEASES Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses Pia Trip 1, Esther J. Nossent
More informationPulmonary Hypertension: Clinical Features & Recent Advances
Pulmonary Hypertension: Clinical Features & Recent Advances Lisa J. Rose-Jones, MD Assistant Professor of Medicine, Division of Cardiology Advanced Heart Failure/Cardiac Transplantation & Pulmonary Hypertension
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Draft remit / appraisal objective: Draft scope To appraise the clinical and cost effectiveness
More informationSCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW
SCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW Lung disease can be a serious complication of scleroderma. The two most common types of lung disease in patients with scleroderma are interstitial
More informationThe Case of Marco Nazzareno Galiè, M.D.
The Case of Marco Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationEffective Strategies and Clinical Updates in Pulmonary Arterial Hypertension
Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension Hap Farber Director, Pulmonary Hypertension Center Boston University School of Medicine Disclosures 1) Honoria: Actelion, Gilead,
More informationΠνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ
Πνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ PH is defined as PAPm 25 mm Hg at rest The general definition of PH remains unchanged Most of the relevant epidemiological and therapeutic studies have used the 25 mm
More informationTBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than
TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than PAP) BAL is not required as a diagnostic tool in patients
More informationPaediatric PAH in the current era
Paediatric PAH in the current era Dunbar Ivy, MD The Children s Hospital Heart Institute University of Colorado School of Medicine Paediatric PAH in the current era & A Gap Analysis Dunbar Ivy, MD The
More informationMACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH)
MACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH) ORPHAN DRUG AND RARE DISEASE 11 MAY 2017 Catherine Lesage, MD, Pediatrics Program Head, Actelion Copyright AGENDA Pulmonary Arterial
More informationINTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018
INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial
More informationPulmonary hypertension in sarcoidosis
Pulmonary hypertension in sarcoidosis Olivier SITBON Centre de Référence de l Hypertension Pulmonaire Sévère Hôpital Universitaire de Bicêtre INSERM U999 Université Paris-Sud Le Kremlin-Bicêtre France
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.10 Subject: Uptravi Page: 1 of 6 Last Review Date: September 15, 2017 Uptravi Description Uptravi
More informationPulmonary hypertension. Miloslav Špaček, MD
Pulmonary hypertension Miloslav Špaček, MD Key points Pulmonary hypertension (PH) is a hemodynamic and pathophysiological abnormality found in many clinical conditions, most commonly heart and lung disease
More informationCautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease
Eur Respir J 2009; 34: 1348 1356 DOI: 10.1183/09031936.00017809 CopyrightßERS Journals Ltd 2009 Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease
More information9/15/11. Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September Scleroderma. Hard skin
Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September 2011 Scleroderma Hard skin 1 No diagnostic test for scleroderma Pathogenesis is unknown prominent features of disease reflect
More informationCase 1: Question. 1.1 What is the main pattern of this HRCT? 1. Intralobular line 2. Groundglass opacity 3. Perilymphatic nodule
HRCT WORK SHOP Case 1 Case 1: Question 1.1 What is the main pattern of this HRCT? 1. Intralobular line 2. Groundglass opacity 3. Perilymphatic nodule Case 1: Question 1.2 What is the diagnosis? 1. Hypersensitivity
More informationERDHEIM-CHESTER DISEASE LUNG & HEART ISSUES
ERDHEIM-CHESTER DISEASE LUNG & HEART ISSUES GIULIO CAVALLI, M.D. INTERNAL MEDICINE AND CLINICAL IMMUNOLOGY IRCCS SAN RAFFAELE HOSPITAL VITA-SALUTE SAN RAFFAELE UNIVERSITY MILAN, ITALY cavalli.giulio@hsr.it
More informationPulmonary Hypertension. Murali Chakinala, M.D. Washington University School of Medicine
Pulmonary Hypertension Murali Chakinala, M.D. Washington University School of Medicine Pulmonary Circulation Alveolar Capillary relationship Pulmonary Circulation High flow, low resistance PVR ~1/15 of
More informationADVANCED THERAPIES FOR PHARMACOLOGICAL TREATMENT OF PULMONARY HYPERTENSION
Status Active Medical and Behavioral Health Policy Section: Medicine Policy Number: II-107 Effective Date: 04/21/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.13 Section: Prescription Drugs Effective Date: July 1 2016 Subject: Tyvaso Page: 1 of 4 Last Review
More informationSudden Death in a Patient with Pulmonary Veno-occlusive Disease (PVOD) and Severe Pulmonary Hypertension
CASE REPORT Sudden Death in a Patient with Pulmonary Veno-occlusive Disease (PVOD) and Severe Pulmonary Hypertension Minako Saito 1, Nobuharu Ohshima 2, Hirotoshi Matsui 1, Akira Hebisawa 3 and Ken Ohta
More informationPulmonary Arterial Hypertension: The Approach to Management in 2019
Pulmonary Arterial Hypertension: The Approach to Management in 2019 Munir S. Janmohamed M.D. FACC Medical Director Mechanical Circulatory Support/Heart Failure Program Mercy General Hospital/Mercy Medical
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.21 Subject: Orenitram Page: 1 of 6 Last Review Date: June 24, 2016 Orenitram Description Orenitram
More informationThe Hemodynamics of PH Interpreting the numbers
The Hemodynamics of PH Interpreting the numbers Todd M Bull MD Associate Professor of Medicine Division of Pulmonary Sciences and Critical Care Medicine Pulmonary Hypertension Center University of Colorado
More informationNavigating the identification, diagnosis and management of pulmonary hypertension using the updated ESC/ERS guidelines
Navigating the identification, diagnosis and management of pulmonary hypertension using the updated ESC/ERS guidelines Host: Marc Humbert Speaker: Simon Gibbs Marc HUMBERT, MD, PhD Professor of Respiratory
More informationCentrilobular nodules in high resolution computed tomography of the lung in IPAH patients preliminary data concerning clinico-radiological correlates
ORIGINAL RESEARCH Monika Szturmowicz 1, Aneta Kacprzak 1, Barbara Burakowska 2, Agnieszka Skoczylas 3, Iwona Bestry 2, Jan Kuś 1, Anna Fijałkowska 4, Adam Torbicki 5, Marcin Kurzyna 5 1 I st Department
More informationACTIVITY DESCRIPTION Target Audience Learning Objectives
ACTIVITY DESCRIPTION Target Audience This continuing medical education activity is planned to meet the needs of primary care physicians who can contribute to early detection of disease and who are responsible
More informationREVATIO (sildenafil)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence
More informationSystemic lupus erythematosus (SLE): Pleuropulmonary Manifestations
08/30/10 09/26/10 Systemic lupus erythematosus (SLE): Pleuropulmonary Manifestations Camila Downey S. Universidad de Chile, School of Medicine, Year VII Harvard University, School of Medicine Sept 17,
More informationA 50-Year-Old Woman With Dyspnea, Lower Extremity Edema, and Volume Loss of the Right Hemithorax. Eugene Shostak, MD; and Akmal Sarwar, MD, FCCP
CHEST A 50-Year-Old Woman With Dyspnea, Lower Extremity Edema, and Volume Loss of the Right Hemithorax Eugene Shostak, MD; and Akmal Sarwar, MD, FCCP Postgraduate Education Corner PULMONARY AND CRITICAL
More informationSA XXXX Special Authority for Subsidy
SA XXXX Special Authority for Subsidy Special authority approved by the Pulmonary Arterial Hypertension (PAH) Panel. Application forms can be obtained from PHARMAC s website: www.pharmac.govt.nz or: PAH
More informationADCIRCA (tadalafil) The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence
More informationΠνευμονική υπέρταση: Τα 10 πιο σημαντικά κενά και παραλείψεις των Κατευθυντήριων Οδηγιών του 2015
Πνευμονική υπέρταση: Τα 10 πιο σημαντικά κενά και παραλείψεις των Κατευθυντήριων Οδηγιών του 2015 Γεωργία Γ. Πίτσιου, MD, MSc, PhD Πνευμονολόγος- Εντατικολόγος Επίκουρη Καθηγήτρια Ιατρική Σχολή ΑΠΘ Γ.Ν.
More informationPharmacy Management Drug Policy
SUBJECT: Pulmonary Arterial Hypertension (PAH) POLICY NUMBER: Pharmacy-42 Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed
More informationPulmonary Hypertension: Classification
Pulmonary Hypertension: Pathophysiology and Classification M. Maggiorini Medical Intensive Care Unit University Hospital Zürich Pulmonary hypertension is a disease of the pulmonary circulation with many
More informationRecent Treatment of Pulmonary Artery Hypertension. Cardiology Division Yonsei University College of Medicine
Recent Treatment of Pulmonary Artery Hypertension Cardiology Division Yonsei University College of Medicine Definition Raised Pulmonary arterial pressure (PAP) WHO criteria : spap>40 mmhg NIH Criteria
More informationPDE5 INHIBITOR POWDERS Sildenafil powder, Tadalafil powder
RATIONALE FOR INCLUSION IN PA PROGRAM Background Sildenafil and Tadalafil are marketed as Revatio and Adcirca for pulmonary arterial hypertension. This is a rare disorder of the pulmonary arteries in which
More informationLung diseases of Vascular Origin. By: Shefaa Qa qqa
Lung diseases of Vascular Origin By: Shefaa Qa qqa Pulmonary Hypertension Pulmonary hypertension is defined as a mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest. Based on underlying
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.16 Subject: Letairis Page: 1 of 6 Last Review Date: June 24, 2016 Letairis Description Letairis (ambrisentan)
More informationSafety and Efficacy of Epoprostenol Therapy in Pulmonary Veno-Occlusive Disease and Pulmonary Capillary Hemangiomatosis
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Pulmonary Circulation Safety and Efficacy of Epoprostenol Therapy in Pulmonary Veno-Occlusive
More informationDifferential diagnosis
Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential
More informationRole of pulmonary vasodilators in the Fontan setting. Michael Cheung Melbourne
Role of pulmonary vasodilators in the Fontan setting Michael Cheung Melbourne Fontan circuit Low resistance to adequate pulmonary blood flow is critical Central PA anatomy (size and distortion) Intrapulmonary
More informationSqueeze, Squeeze, Squeeze: The Importance of Right Ventricular Function and PH
Squeeze, Squeeze, Squeeze: The Importance of Right Ventricular Function and PH Javier Jimenez MD PhD FACC Director, Advanced Heart Failure and Pulmonary Hypertension Miami Cardiac & Vascular Institute
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Tracleer Page: 1 of 6 Last Review Date: September 15, 2017 Tracleer Description Tracleer (bosentan)
More informationDisclosures. Inhaled Therapy in Pediatric Pulmonary Hypertension. Inhaled Prostacyclin: Rationale. Outline
Disclosures Inhaled Therapy in Pediatric Pulmonary Hypertension The University of Colorado receives fees for Dr Ivy to be a consultant for Actelion, Gilead, Lilly, Pfizer, and United Therapeutics Dunbar
More informationPediatric Pulmonary Hypertension: Inside Out
Pediatric Pulmonary Hypertension: Inside Out Asma Razavi, MD Assistant Professor Pediatric Critical Care Medicine Loma Linda University Children s Hopsital Disclosures I have no conflicts of interest to
More informationNeonatal and Pediatric Pulmonary Vascular Disease
Neonatal and Pediatric Pulmonary Vascular Disease Emma Olson, MS, ARNP Pediatric Cardiology Nurse Practitioner Canadian Respiratory Conference April 14, 2018 Financial Interest Disclosure (over the past
More informationOut of proportion pulmonary hypertension
IPF the missing link Out of proportion pulmonary hypertension Rome 29-30 May 2015 Sergio Harari U.O. di Pneumologia e UTIR Servizio di Emodinamica e Fisiopatologia Respiratoria Ospedale San Giuseppe -
More informationPulmonary hypertension and granulomatous vasculitis in sarcoidosis Hidenobu Shigemitsu, Sonoko Nagai and Om P. Sharma
Pulmonary hypertension and granulomatous vasculitis in sarcoidosis Hidenobu Shigemitsu, Sonoko Nagai and Om P. Sharma Purpose of review To examine the recent advancements of the epidemiology, pathophysiology,
More informationDilated Cardiomyopathy in Dogs
Dilated Cardiomyopathy in Dogs (a Type of Heart-Muscle Disease) Basics OVERVIEW The heart of the dog is composed of four chambers; the top two chambers are the left and right atria and the bottom two chambers
More informationTHERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines
THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines Vu Nang Phuc, MD Dinh Duc Huy, MD Pham Nguyen Vinh, MD, PhD, FACC Tam Duc Cardiology Hospital Faculty Disclosure No conflict of interest
More informationPulmonary Hypertension. Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes
Pulmonary Hypertension Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes Pulmonary Arterial Hypertension Disease of small pulmonary arteries Characteristic changes Medial hypertrophy Intimal
More informationAcute Respiratory Distress Syndrome (ARDS) An Update
Acute Respiratory Distress Syndrome (ARDS) An Update Prof. A.S.M. Areef Ahsan FCPS(Medicine) MD(Critical Care Medicine) MD ( Chest) Head, Dept. of Critical Care Medicine BIRDEM General Hospital INTRODUCTION
More informationCor pulmonale. Dr hamid reza javadi
1 Cor pulmonale Dr hamid reza javadi 2 Definition Cor pulmonale ;pulmonary heart disease; is defined as dilation and hypertrophy of the right ventricle (RV) in response to diseases of the pulmonary vasculature
More informationAdvances in Pharmacotherapy of PAH
24 th Annual Advances in Heart Disease Advances in Pharmacotherapy of PAH Gabriel Gregoratos, MD 12/14/2007 UCSF Cardiology 1 Faculty Disclosure Statement for Gabriel Gregoratos, MD Nothing to disclose
More informationChallenges in pulmonary hypertension: managing the unexpected
CASE-BASED REVIEW PULMONARY HYPERTENSION Challenges in pulmonary hypertension: managing the unexpected Karen M. Olsson 1 and Massimiliano Palazzini 2 Affiliations: 1 Dept of Respiratory Medicine, Hannover
More informationPulmonary hypertension
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2012 Pulmonary hypertension Glaus, T M Posted at the Zurich Open Repository
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.17 Subject: Remodulin Page: 1 of 5 Last Review Date: June 24, 2016 Remodulin Description Remodulin
More informationImaging Cancer Treatment Complications in the Chest
Imaging Cancer Treatment Complications in the Chest Michelle S. Ginsberg, MD Objectives Imaging Cancer Treatment Complications in the Chest To understand the mechanisms of action of different classes of
More information5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +
More informationMultimodality imaging for PAH: Is CT better than MRI?
UNIVERSITÀ DEGLI STUDI DI TORINO Facoltà di Medicina e Chirurgia Dipartimento di Scienze Chirurgiche Istituto di Radiologia Azienda Ospedaliera Universitaria Città della Salute e della scienza di Torino
More informationPulmonary Hypertension Perioperative Management
Pulmonary Hypertension Perioperative Management Bruce J Leone, MD Professor of Anesthesiology Chief, Neuroanesthesiology Vice Chair for Academic Affairs Mayo Clinic Jacksonville, Florida Introduction Definition
More informationIn focus The paediatric PAH population Clinicians Perspectives
In focus The paediatric PAH population Clinicians Perspectives Maurice Beghetti Pediatric Cardiology University Children s Hospital HUG and CHUV Pulmonary Hypertension Program HUG Centre Universitaire
More informationPulmonary Arterial Hypertension: Biomarkers and Treatment
Pulmonary Arterial Hypertension: Biomarkers and Treatment Demos Papamatheakis, MD Assistant Clinical Professor Division of Pulmonary, Critical Care and Sleep Medicine UC San Diego Health Definition EHJ
More informationChromosome 15 Chromosome 17 Chromosome 20
Chromosome 1 Chromosome 6 Chromosome 11 Chromosome 15 Chromosome 17 Chromosome 20 Supplementary figure 1. Regions of suggestive linkage in PVOD families 1,2 and 3. Six regions were identified with suggestive
More information11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.15 Subject: Flolan Veletri Page: 1 of 5 Last Review Date: September 15, 2017 Flolan Veletri Description
More informationTREPROSTINIL Generic Brand HICL GCN Exception/Other TREPROSTINIL REMODULIN 23650
Generic Brand HICL GCN Exception/Other TREPROSTINIL REMODULIN 23650 SODIUM TREPROSTINIL TYVASO 36537 36539 36541 TREPROSTINIL ORENITRAM 40827 **Please use the criteria for the specific drug requested**
More informationDIAGNOSTIC NOTE TEMPLATE
DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the
More informationΚαθετηριασμός δεξιάς κοιλίας. Σ. Χατζημιλτιάδης Καθηγητής Καρδιολογίας ΑΠΘ
Καθετηριασμός δεξιάς κοιλίας Σ. Χατζημιλτιάδης Καθηγητής Καρδιολογίας ΑΠΘ The increasing interest in pulmonary arterial hypertension (PAH), the increasing interest in implantation of LVADs, and the evolution
More informationUpdate in Pulmonary Arterial Hypertension
Update in Pulmonary Arterial Hypertension Michael J Sanley, MD April 12, 2018 Disclosures I have nothing to disclose 2 1 Case Presentation 67 yo male with atrial fibrillation, CLL on IVIG, presents with
More informationCARDIO-VASCULAR SYNDROME
CARDIO-VASCULAR SYNDROME Dr Etienne Leroy-Terquem Centre hospitalier de Meulan les Mureaux. France French-cambodian association for pneumology (OFCP) OFCP Right pulmonary artery Left pulmonary artery
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency London, 18 December 2008 Doc. Ref. EMEA/CHMP/EWP/356954/2008 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT CHMP GUIDELINE ON THE CLINICAL INVESTIGATIONS OF MEDICINAL
More informationCurrent and Emerging Drugs in Pulmonary Vascular Pharmacology Dr AS Paul DM Seminar 08 September 06
Current and Emerging Drugs in Pulmonary Vascular Pharmacology Dr AS Paul DM Seminar 08 September 06 Pulmonary Hypertension A mean pressure of greater than 25 mm Hg at rest (normal ~14 mm Hg) or greater
More information4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs
Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation
More informationdifferent phenotypes
Pulmonary hypertension in scleroderma: different phenotypes UMR 995 Pr David LAUNAY, MD, PhD launayd@gmail.com Service de Médecine Interne. Unité d'immunologie Clinique CNRMR Maladies Systémiques et Autoimmunes
More informationELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY
ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY Contents Eligibility criteria for Pulmonary Arterial Hypertension therapy...2-6 Initial Application for funding of Pulmonary Arterial Hypertension
More informationThe role of Pulmonary function Testing In Interstitial lung disease in infants. [ ipft in child ]
The role of Pulmonary function Testing In Interstitial lung disease in infants [ ipft in child ] Introduction Managing infants with diffuse lung disease (DLD) suspected to have interstitial lung disease
More informationPulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension
Respiratory Medicine (2010) 104, 481e496 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed REVIEW Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary
More informationPulmonary Arterial Hypertension (PAH) Treatments
Care1st Health Plan Arizona, Inc. Easy Choice Health Plan Harmony Health Plan of Illinois Missouri Care Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona OneCare (Care1st Health
More informationScleroderma and PAH Overview. PH Resource Network Martha Kingman, FNP C UTSW Medical Center at Dallas
Scleroderma and PAH Overview PH Resource Network 2007 Martha Kingman, FNP C UTSW Medical Center at Dallas Scleroderma and PAH Outline: Lung involvement in scleroderma Evaluation of the scleroderma patient
More informationSildenafil Citrate Powder. Sildenafil citrate powder. Description. Section: Prescription Drugs Effective Date: January 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.15 Subject: Sildenafil Citrate Powder Page: 1 of 6 Last Review Date: December 3, 2015 Sildenafil Citrate
More informationΕιδικές θεραπείες σε µη-αρτηριακή πνευµονική υπέρταση, πότε; - Στέλλα Μπρίλη Α Πανεπιστηµιακή Καρδιολογική Κλινική Ιπποκράτειο Νοσοκοµείο Αθηνών
Ειδικές θεραπείες σε µη-αρτηριακή πνευµονική υπέρταση, πότε; - Στέλλα Μπρίλη Α Πανεπιστηµιακή Καρδιολογική Κλινική Ιπποκράτειο Νοσοκοµείο Αθηνών . Updated Clinical Classification of Pulmonary Hypertension
More informationPathology of pulmonary vascular disease. Dr.Ashraf Abdelfatah Deyab. Assistant Professor of Pathology Faculty of Medicine Almajma ah University
Pathology of pulmonary vascular disease Dr.Ashraf Abdelfatah Deyab Assistant Professor of Pathology Faculty of Medicine Almajma ah University Pulmonary vascular disease Type of pulmonary circulation: Types
More informationDr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college
Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college PULMONARY HYPERTENSION Difficult to diagnose early Because Not detected during routine physical examination and Even in advanced cases symptoms
More informationEffectively treating patients with pulmonary hypertension: The next chapter. Lowering PAP will improve RV function in PH
Effectively treating patients with pulmonary hypertension: The next chapter Stuart Rich, M.D. Hemodynamic Progression of PAH Preclinical Symptomatic/ Stable Pulmonary Pressure Progressive/ Declining Level
More informationScreening for CETPH after acute pulmonary embolism: is it needed? Menno V. Huisman Department of Vascular Medicine LUMC Leiden
Screening for CETPH after acute pulmonary embolism: is it needed? Menno V. Huisman Department of Vascular Medicine LUMC Leiden m.v.huisman@lumc.nl Background CETPH Chronic Thrombo Embolic Pulmonary Hypertension
More informationCASE REPORT. Case Report. Introduction. Shojiro Minomo 1, Masanori Kitaichi 2, Toru Arai 1,3, Hideo Matsui 1, Masanori Akira 4 and Yoshikazu Inoue 1,3
doi: 10.2169/internalmedicine.0681-17 Intern Med Advance Publication http://internmed.jp CASE REPORT Pulmonary Veno-occlusive Disease: A Surgical Lung Biopsy-proven and Autopsied Case Radiologically Mimicking
More informationPulmonary Hypertension: ICD-10 I27.0, I27.2
Dr Manish Barman, MD. Membership and Affiliations ESC, European association of cardiovascular prevention and rehabilitation. Acute Cardiovascular Care Association. ESC, Working Group on Hypertension &
More informationPulmonary Manifestations of Systemic Lupus Erythematosus 1
Pulmonary Manifestations of Systemic Lupus Erythematosus 1 Kee Hyuk Yang, M.D., Yo Won Choi, M.D., Seok Chol Jeon, M.D., Choong Ki Park, M.D., Kyung in Joo, M.D., Chang Kok Hahm, M.D., Seung Ro Lee, M.D.
More informationA case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel
A case of a patient with IPF treated with nintedanib Prof. Kreuter and Prof. Heussel Case Overview This case describes the history of a patient with IPF who, at the time of diagnosis, had symptoms typical
More information